Document Detail


Very small size proteoliposomes (VSSP) and Montanide combination enhance the humoral immuno response in a GnRH based vaccine directed to prostate cancer.
MedLine Citation:
PMID:  22921738     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Very small size proteoliposomes (VSSP) constitute a complex of very small size proteoliposomes that includes proteins, lipids, CpG and gangliosides tumor-associated that provides a potential target for cancer immunotherapy. This compound has been described to stimulate the humoral and cellular response, dendritic cells (DC) activation and differentiation of T-helper cells, specially, in immunocompromised patients with cancer status. This work deals with the stimulating capacity of the VSSP to reach a humoral response when they are used as a component in a peptidic vaccine based on the gonadotrophin releasing hormone (GnRH). This study was carried out in male Copenhagen rats, which were immunized with 750μg of the GnRH mimetic peptide (GnRHm1-TT) with or without the VSSP. The mixtures were always emulsified with the oil adjuvant Montanide ISA 51. The anti GnRH seroconversion analysis revealed that the group immunized with the peptide GnRHm1-TT/VSSP developed a strong anti GnRH seroconversion. These antibody levels proved to be significant superior to those reached by the use of the GnRHm1-TT peptide solely emulsified in Montanide. Post-mortem analysis on the Testosterone ablation target organs (prostate and testicles) yielded a sudden decrease in their size and weight in respect to the control group. On the other hand, the group submitted to the use of GnRHm1-TT/VSSP, showed a significant difference in the reduction of these target organs in comparison with the group only immunized with GnRHm1-TT adjuvated in Montanide ISA 51. These values turned to be of p=0.023 and p=0.009 in the prostate and testicles respectively. These findings foreground the VSSP as a useful immunopotentiator to be used as part of a GnRH based vaccine to treat prostate cancer.
Authors:
Franklin Fuentes Aguilar; Jesús Junco Barranco; Eddy Bover Fuentes; Lesvia Calzada Aguilera; Yovisleydis Lopez Sáez; María Dolores Castro Santana; Eulogio Pimentel Vázquez; Roberto Basulto Baker; Osvaldo Reyes Acosta; Hilda Garay Pérez; Gerardo Guillén Nieto
Related Documents :
24312658 - Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 ...
15995948 - The novel oral typhoid vaccine m01zh09 is well tolerated and highly immunogenic in 2 va...
23479678 - Long-term vaccination with multiple peptides derived from cancer-testis antigens can ma...
18706948 - Effects of salmonella enterica serovar enteritidis on cellular recruitment and cytokine...
2001178 - Immunological and virological characterization of improved construction of recombinant ...
20464218 - Relevance of helicobacter pylori virulence factors for vaccine development.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-22
Journal Detail:
Title:  Vaccine     Volume:  -     ISSN:  1873-2518     ISO Abbreviation:  Vaccine     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-8-27     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8406899     Medline TA:  Vaccine     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Ltd. All rights reserved.
Affiliation:
Centro de Ingeniería Genética y Biotecnología Camagüey, Cuba.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Individual variation in biomarkers of health: Influence of persistent organic pollutants in Great sk...
Next Document:  Acute exercise enhancement of pneumococcal vaccination response: a randomised controlled trial of we...